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ABSTRACT
Objective: To investigate the influence of cancer severity and functional status of cancer patients on cardiac parasympathetic indicators.
Methods: A total of 267 patients with a fresh clinical diagnosis of solid malignant tumor not yet put on cancer therapy and 250 controls matched 
for age, sex of study subjects were included. Severity of cancer was defined based on the American Joint Committee on Cancer staging. Accordingly, 
study subjects were subdivided into early stage (Stage I and II combined) and advanced stage (Stage III and IV combined). In cancer patients, the 
Eastern Cooperative Oncology Group (ECOG) performance score and the Faces Pain Scale score (FPS) was noted. Two indicators of vagal function, 
expiratory:inspiratory ratio (E:I ratio) and root mean square of successive N-N interval difference (r-MSSD) were included. E:I ratio during deep 
breathing at six respiratory cycles/minute and r-MSSD at rest was obtained from 1 minute lead II electrocardiogram. Data were analyzed by applying 
suitable statistical tests. p≤0.05 was considered significant.
Results: R-MSSD and E:I ratio was significantly reduced in the early and advanced stage of cancer compared to controls (p≤0.0001). r-MSSD and E:I 
ratio was significantly reduced in advanced stage compared to the early stage of cancer (p≤0.0001). r-MSSD and E:I ratio was significantly different 
in subgroups of stages of cancer and controls (p≤0.0001). In cancer patients, r-MSSD was negatively correlated with ECOG and FPS score (p≤0.0278, 
p≤0.0100).
Conclusion: Severity of cancer affects vagal function. However, r-MSSD alone was associated with functional status (ECOG, FPS) of cancer patients.
Keywords: Cancer, Eastern Cooperative Oncology Group score, Faces pain scale score, Vagal function.
INTRODUCTION
The autonomic nervous system (ANS) not only plays a major role in 
physiological situations but also in various pathological conditions 
such as diabetic neuropathy, myocardial infarction [1,2]. ANS controls 
most of the viscera, and many solid cancers are formed in the same 
viscera [3,4]. Consequently, recent studies have revealed autonomic 
dysfunction in cancer patients [5]. In support of this view our previous 
study on association between ANS and cancer reduced cardiac 
vagal function was observed in cancer patients compared to healthy 
individuals [6]. Further, in a relatively small sample size, we also 
observed that vagal function declines with severity of cancer [7]. These 
study findings, warrants confirming the same in a larger sample size. 
At present, cancer research is looking into the possibility of heart rate 
variability (HRV) parameters as a prognosticator of cancer.
HRV is a simple non-invasive tool for assessing ANS function [8]. 
HRV parameters are commonly used in both normal subjects and in 
various clinical conditions [9,10]. Among the HRV parameters, root 
mean square of successive N-N interval difference (r-MSSD) and 
expiratory inspiratory ratio (E:I ratio) are the two known indicators 
of cardiac parasympathetic function [11]. At present, severity of 
cancer is evaluated based on the findings of histopathological report 
and patients are staged as per American Joint Committee on Cancer 
(AJCC) staging [12]. In oncology, Faces Pain Scale (FPS) and the Eastern 
Cooperative Oncology Group score (ECOG) have been applied extensively 
to assess the functional status of cancer patients. FPS is a visual analog 
tool to measure intensity of pain endured by an individual [13,14]. 
Studies have revealed an association between experimental pain and 
ANS in healthy individuals [15,16]. Nonetheless, studies on association 
between autonomic function and pain in cancer are not documented. 
ECOG performance status score has been widely used in clinical set 
up to assess general functional condition in cancer patients [17]. In 
cancer patients, ECOG score was widely applied for survival analysis 
in an advanced stage of cancer [18]. Indices of parasympathetic 
function are considered to be independent predictors of mortality in 
health and disease conditions including cancer [19-22]. However, no 
data are available on the relationship between cardiac vagal function 
and ECOG score in cancer patients. Therefore, based on the need for 
a novel prognostic factor in solid malignant tumor patients, and to 
further elucidate the association between cardiac parasympathetic 
function and pathogenesis of cancer this study aimed at investigating 
the influence of tumor burden (severity) and functional status of cancer 
patients on cardiac parasympathetic indicators.
METHODS
This was a hospital based cross-sectional study conducted in Kasturba 
Medical College and Hospital, Mangalore, India. This study was 
conducted after obtaining Institutional Ethics Committee approval (Ref: 
IEC KMC MLR 03-14/77 dated 19th March 2014) and informed consent 
from study participants. All procedures were undertaken according to 
the Declaration of Helsinki.
Study subjects
This study involved 267 patients with a solid malignant tumor 
who were freshly diagnosed with head and neck cancer (n=104), 
gastrointestinal (n =82), and gynecological cancer (n=81). Among the 
study subjects recruited, based on the American Joint Committee of 
Cancer staging [12]: 22 were with Stage I, 62 with Stage II, 96 with Stage 
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III, and 87 were with Stage IV. Stage I and II were combined together to 
form the early stage and Stage III and IV were considered the advanced 
stage of cancer. Control group was comprised 250 healthy subjects who 
were matched for age and sex of study subjects.
Inclusion and exclusion criteria
Cancer patients either with head and neck or gastrointestinal or 
gynecological cancer alone and who were not yet put on any treatment 
were included. Exclusion criteria included patients with cardiovascular 
disease, implanted pacemaker, ectopic beats and patients on cardiac 
medication (anti-arrhythmic drugs, b-blockers), history of diabetes, 
hypertension, thyroid diseases, abnormal breathing, and chronic 
obstructive pulmonary disease. Patients in whom tumor extended 
up to the cervical sympathetic chain or any other conditions known 
to alter vagal function or influence inflammation such as arthritis or 
inflammatory diseases were excluded.
Study protocol and procedure
All the test procedures were explained to the study participants before 
starting the study. All the subjects in the study and control groups 
underwent clinical examination. However, study subjects alone were 
subjected to a detailed physical examination.
Clinical measurements
Information on functional status and intensity of pain endured by an 
individual was assessed by the ECOG performance status and FPS in 
study subjects alone. The ECOG performance status is widely used as 
a clinical indicator for general functional condition, and it is defined 
as follows: 0 meant for normal function, 1 used for bare minimum 
functional impairment, 2 used for spending time in bed for <50%, 3 for 
impairment amounting to spending more than 50% of time in bed, 
and 4 used for completely bed ridden, and 5 accounts for death [17]. 
In this study, ECOG score was noted from the case sheet of the patients 
as evaluated and documented by the oncologist. FPS measures the 
intensity of the pain endured by the subjects: 0 - Very happy no pain, 
2 - Hurts little bit, 4 - Hurts more than a little, 6 - Hurts to greater extent, 
8 - Hurts a whole lot, and 10 - Hurts more than imagined (don’t have to 
be crying to feel this much pain) [13].
FPS chart:
Each patient was asked to state the pain endured by them according 
to the FPS chart provided to them and then FPS was noted. Stage of 
cancer was noted from the oncologists’ report which is based on 
histopathological report and defined by AJCC criteria followed for 
staging of cancer [12].
In addition, to routine general examination in both study and control 
subjects, the body mass index (BMI), blood pressure (BP), and Heart 
rate (HR) were recorded. For calculating BMI, first, the height and 
weight of all the subjects were measured. BMI was calculated using 
the formula: Weight in kilograms (kg) divided by height in meters (m) 
squared [23]. BP was measured using sphygmomanometer in sitting 
position. Both systolic and diastolic pressure was measured in all the 
subjects and mean of two readings was taken as BP. HR was obtained 
from counting the total number of R-R intervals in 1-minute lead II 
electrocardiogram (ECG) recorded in supine position in subjects after 
giving them sufficient rest of 5 minutes.
Vagal nerve activity assessment
In study and control subjects, vagal nerve function was assessed by 
quantifying the following parameters, namely, expiratory:inspiratory 
ratio (E:I ratio) and r-MSSD. In this study for assessing vagal nerve 
function in subjects, 1-minute lead II ECG was used. In all the subjects, 
1-minute lead II ECG was recorded at a speed of 25 mm/s for 60 seconds 
using Cardiart 108T/MKVII, BPL Ltd. Bengaluru, Karnataka, India. ECG 
recordings were carried out in the supine position after subjects were 
given sufficient rest of 15 minutes.
Assessment of E:I ratio in response to deep breathing
Deep breathing test was conducted in the morning after the subjects 
were given complete rest. Each subject was taught to breathe at six 
breaths per minute. That is 5 seconds for each inhalation and 5 seconds 
for each exhalation. Once the subjects were comfortable enough 
to breath at 6 respiratory cycles per minute, study procedure was 
conducted. Subjects were instructed to follow the commands of the 
examiner. Then, the examiner raised his hand to signal the start of each 
inhalation and lowered his hand to signal the start of each exhalation. 
Simultaneously lead II ECG was recorded at the speed of 25 mm/s for 
60 seconds while the subject breathed as instructed (Cardiart 108T/
MKVII, BPL Ltd. Bangalore, Karnataka, India). After the recording of ECG, 
each R-R intervals were measured accurately. The longest R-R interval 
during expiration and the shortest R-R interval during inspiration was 
expressed as E:I ratio [24].
Assessment of r-MSSD
r-MSSD was estimated from 1 minute resting lead II ECG tracing. ECG 
recording was obtained after the subject was lying in a supine position 
in completely relaxed state. Each of the R-R intervals were measured 
accurately and computed. Then, r-MSSD was estimated by applying 
suitable statistical functions using Microsoft Windows XP Professional 
(Microsoft Corporation, Redmond, WA, USA) [25,26].
Statistical analysis
Unpaired t-test/Mann–Whitney U statistic was used to compare 
between two different groups. One-way ANOVA/Kruskal–Wallis (KW) 
test followed by multiple comparisons was used to compare when the 
groups were more than two. The Pearson correlation coefficient test 
was used to find the correlation between two groups. The level of 
significance was determined by a two-tailed test. p<0.05 was taken as 
significant.
RESULTS
Baseline characteristics in study and control subjects
In a total of 267 study subjects, 136 were females, and 131 were males. 
Among, these study subjects 209 had squamous cell carcinoma, 56 were 
with adenocarcinoma, and 2 were with mucoepidermoid carcinoma. 
The study subjects were with three primary sites of malignant tumor: 
Gynecological (n=81); gastrointestinal (n=82); head and neck (n=104). 
The mean age of the study subjects among these three sites of the 
primary tumor was comparable (gynecological: 52.06±8.26 years; 
gastrointestinal: 53.59±9.49 years; head and neck: 53.01±10.52 years; 
one-way ANOVA F=0.5365, p≤0.5855). In study subjects mean ECOG 
score was 1.38±0.60 and mean FPS score was 3.51±2.26.
The data on comparison of baseline characteristics between study and 
control groups is presented in Table 1. BMI was significantly lower in the 
study group compared to controls (Mann–Whitney U-statistic=19916.0; 
p≤0.0001, Table 1). HR was significantly higher in the study group 
compared to controls (Mann–Whitney U-statistic=25472.0, p≤0.0001, 
Table 1). Age, systolic BP, and diastolic BP did not differ significantly 
between study and control group (Table 1).
Vagal nerve functions in early stage and advanced stage of cancer 
compared to control group
Data on vagal nerve function in early stage and advanced stage of 
cancer compared to control group are presented in Table 2. r-MSSD and 
E:I ratio was significantly different among control, early and advanced 
stage of cancer (KW=178.13, p<0.001; 329.16, p<0.0001, respectively). 
(KW=178.13 p<0.0001; 329.16, p<0.0001, respectively) r-MSSD and 
E:I ratio was significantly lower in the early stage and advanced stage of 
cancer compared to control group (p≤0.0001, Table 2).
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Comparison of vagal nerve functions between early and advanced 
stage of cancer in study subjects
Data on comparison between early stage and advanced stage of cancer 
are presented in Figs. 1 and 2. r-MSSD and E:I ratio was significantly 
lower in the advanced stage of cancer compared to early stage 
(p≤0.0001, Figs. 1 and 2, respectively).
Vagal nerve functions in different stages of cancer in study group 
compared to control group
Data on vagal nerve function parameters in different stages of cancer and 
control are presented in Table 3. r-MSSD and E:I ratio was significantly 
different in subgroups of stages of cancer and control group (KW 
test=185.47, 331.89; p≤0.0001, Table 3). E:I ratio was significantly less 
in Stage 1, Stage II, Stage III, and IV compared to control group (Table 3). 
r-MSSD was significantly different in Stage II, Stage III, and IV compared 
to control group (Table 3). There was no significant difference in 
r-MSSD between Stage I and control group (Table 3). In study subjects, 
there was no significant difference in E:I ratio and r-MSSD between 
Stage I and II (Table 3). There was no significant difference in E:I ratio 
and r-MSSD between Stage III and IV (Table 3).
Correlation between r-MSSD and ECOG and FPS score in study 
group
Data on the correlation between r-MSSD and ECOG score and FPS score 
in the study group are presented in Figs. 3 and 4, respectively. Significant 
negative correlation was observed between r-MSSD and ECOG score 
(r=−0.1346, p≤0.0278; Fig. 3). Significant negative correlation was 
observed between r-MSSD and FPS score (r=−0.1575, p≤0.0100; Fig. 4).
Correlation between E:I ratio and ECOG and FPS score in study 
group
ECOG score and FPS score were not significantly correlating with E:I 
ratio (r=0.0813, p≤0.1853; r=−0.0634, p≤0.3017, respectively).
DISCUSSION
This study investigated the association between vagal nerve function and 
severity of cancer. This study also sought its correlation with the functional 
status of these cancer patients (as assessed by ECOG score and FPS).
In this study, r-MSSD and E:I ratio, the two indicators of vagal function 
were significantly reduced in the early and advanced stage of cancer 
compared to healthy subjects (Table 2). Further, in study subjects, 
patients in advanced stage of cancer had a lower vagal function (E:I 
ratio and r-MSSD) compared to the early stage of cancer (Figs. 1 and 2). 
This finding confirms our previous study findings (with the smaller 
sample size) were in it was observed that E:I ratio and r-MSSD declines 
with severity of cancer [7]. Early stages of cancer had lesser tumor 
burden and are with comparatively smaller tumor size and lesser 
nodal metastasis. Whereas, advanced stage of cancer patients are 
generally with greater tumor size, greater lymph node metastasis and 
were with metastasis to distant organs than the primary site of the 
tumor [27]. Therefore, these findings suggest that in cancer patients, 
vagal function deteriorates as the tumor burden increases. De Couck 
et al. also observed low vagal function in advanced stage compared 
to the early stage of cancer but involving only r-MSSD as an indicator 
for vagal function whereas our study involved both E:I ratio and 
r-MSSD [4]. Their study population included comorbid conditions such 
as cardiovascular disease and diabetes which are known to influence 
vagal function indicators whereas our study populations were only 
with cancer.
To further elucidate our study findings, we compared two indicators of 
vagal function, namely, r-MSSD and E:I ratio between different stages 
of cancer and control subjects (Table 3). Both r-MSSD and E:I ratio 





Age (years) 53.40±9.63 52.90±9.55NS
Body mass index (kg/m2) 21.55±2.56 19.56±3.46***
Heart rate (beats/min) 71.66±5.10 74.41±7.39***
Systolic blood pressure (mmHg) 116.03±13.13 119.59±10.37NS
Diastolic blood pressure (mmHg) 79.74±10.95 77.54±6.79NS
***Statistical significant at p≤0.001 compared to control group; 
NSNon-significant compared to control group, n=Sample size. Values are 
expressed as mean±SD. SD: Standard deviation
Table 2: Vagal nerve functions in early stage and advanced stage 








r-MSSD 39.31±12.64 32.31±9.14*** 26.49±4.61***
E:I ratio 1.34±0.08 1.18±0.14*** 1.14±0.06***
***Statistical significant at p≤0.001 compared to control group; 
n=Sample size, values are expressed as mean±SD. SD: Standard deviation, 
E:I: Expiratory:inspiratory ratio, r-MSSD: Root mean square of successive N-N 
interval difference
Fig. 1: Comparison of root mean square of successive N-N interval 
difference (r-MSSD) between early and advanced stage of cancer 
in the study group. ***p≤0.001 compared to the early stage of 
cancer. Sample size n=84 for early stage, n=183 for the advanced 
stage of cancer. Values are expressed as mean±standard deviation
Fig. 2: Comparison of expiratory:inspiratory ratio (E:I ratio) 
between early and advanced stage of cancer in the study group. 
***p≤0.001 compared to the early stage of cancer. Sample size 
n=84 for early stage, n=183 for advanced stage of cancer. Values 
are expressed as mean±standard deviation
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were significantly different in subgroups of stages of cancer and control 
subjects. Among, the two indicators of vagal functions E:I ratio alone 
were decreased in as early as Stage I of cancer compared to control 
group. Whereas, r-MSSD started declining from only Stage II of cancer. 
Therefore, this study finding suggests that vagal function and the onset 
of cancer are interlinked. Thus, this study provides sufficient evidence 
of an association between cancer pathogenesis and vagal function and 
suggests the possibility of considering vagal function as a prognostic 
factor in relation to cancer and its severity.
Among, the two vagal indicators taken into account, r-MSSD was 
negatively correlated with ECOG score (Fig. 3). ECOG score gives 
information regarding physical performance state and is a simple 
measure composed of total six categories which range from being in 
normal activity, at a score of 0, to death, at a score of 5, respectively, 
which remains important in decision-making in terms of cancer 
staging and its prognosis [17]. ECOG score has been well explored in 
terms of its prognostic role in survival values of the advanced stage of 
cancer [18]. However, only one study reported observing a significant 
correlation between ECOG score and HRV parameters. However, 
their study was restricted only to lung cancer patients [28]. In this 
study, we observed vagal function reduced as ECOG score increased 
in cancer patients. A higher ECOG score clinically represents greater 
tumor burden or progressive stage of tumor [17]. In our study, we 
have observed that vagal function deteriorated as stage of cancer 
advanced or tumor burden increased. Moreover, this suggests that 
vagal function and severity of cancer are inversely related. Hence, 
we could imply that low vagal function is associated with poor 
performance status in addition to the consequence of tumor burden 
in cancer.
In this study, r-MSSD was negatively correlating with FPS in cancer 
patients (Fig. 4). FPS is a visual analog pain scale which measures the 
pain endured by an individual with pathological conditions [29]. Pain 
is a complex mechanism and it involves several structures of central 
nervous system, and one among them is ANS [30]. Pain is reportedly 
associated with changes in autonomic dysfunction such as sweating, 
BP variations, and giddiness [31]. Moreover, greater HRV is associated 
with decreased pain sensitivity in normal subjects as assessed by 
FPS [13]. However, no literature dealt with pain and its association 
with vagal function in cancer patients. In this study, we observed 
FPS score increased while vagal function reduced. Pain normally 
accompanies disease and the intensity of pain coincides with the 
disease progression and rise in sympathetic activity and a decrease in 
vagal activity is typically associated with pain [32,33]. Thus, negative 
correlation observed between r-MSSD with FPS score suggests that in 
cancer patient, decrease in vagal function is linked to the intensity of 
pain endured by the patients due to increased tumor burden. Therefore, 
it could be proposed that low vagal function is associated with poor 
performance status (ECOG) and higher perceived pain (FPS) in addition 
to tumor burden.
Findings from this study highlight the important role of r-MSSD in 
quantifying the association of vagal function with tumor burden and 
functional status (ECOG and FPS score) in cancer patients. In oncology, 
cancer stage plays an important part in revealing the prognosis of 
the patient. And our study findings strongly support the view that 
pathogenesis of cancer and vagal function are interlinked. Thus, this 
study provides ample support to consider assessment of vagal function 
as a new prognostic factor in clinical set up in relation to cancer 
patients for screening and monitoring its progression. This study is 
with certain limitations. In our study three sites of cancer, namely, head 
and neck gastrointestinal cancer, and gynecological cancer were pooled 
together, and data were analyzed. Second, we did not quantify standard 
deviation of NN intervals (SDNN) which gives a combined effect of both 
sympathetic and parasympathetic activity. It is well-known that in 
autonomic dysfunction patients vagal nerve is reported to be affected 
at the earliest than sympathetic activity [34], therefore, we did not 
consider SDNN in this study.
Fig. 3: Correlation between root mean square of successive 
N-N interval difference (r-MSSD) and the Eastern Cooperative 
Oncology Group (ECOG) score in study subjects. Sample size 
n=267. Significant negative correlation noted with r=−0.1346 and 
p=0.0278, where Y-axis=ECOG score and X-axis=r-MSSD
Fig. 4: Correlation between root mean square of successive 
N-N interval difference (r-MSSD) and Faces Pain Scale (FPS) 
score in study subjects. Sample size n=267. Significant negative 
correlation noted with r=−0.1575 and p=0.0100, where 
Y-axis=FPS score and X-axis=r-MSSD
Table 3: Vagal nerve functions in four different stages of cancer in study group compared to control group
Vagal function parameters Control (n=250) Stage I (n=22) Stage II (n=62) Stage III (n=96) Stage IV (n=87)
r-MSSD 39.31±12.64 36.45±0.30NSa 30.80±8.62†††NSb 26.85±4.65††† 26.08±4.59†††NSc
E:I ratio 1.34±0.08 1.22±0.08*** 1.17±0.15***NSb 1.14±0.07*** 1.14±0.06NSc
NSaNon significant compared to control group Stage I, and control; NSbNon-significant compared to Stage I; †††Statistical significant at p≤0.001 compared to control; 
***Statistical significant at p≤0.001 compared to control; †††: p ≤ 0.001 compared to control. n=Sample size, values are expressed as mean±SD. SD: Standard deviation, 
E:I: Expiratory:inspiratory ratio, r-MSSD: Root mean square of successive N-N interval difference
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CONCLUSION
Severity of cancer affects vagal nerve functions. Among, the two 
indicators of vagal nerve function, E:I ratio quantifies vagal dysfunction 
at the early stage of cancer. In addition, to this r-MSSD alone was 
associated with the functional status of cancer (ECOG and FPS). E:I ratio 
and r-MSSD could be considered as a new prognostic factor in cancer 
patients for screening and monitoring its progression.
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